TIRADS 5 Thyroid Nodules: Overview, Causes, Symptoms, Treatment, and Biopsy

Thyroid nodules are common findings, and while most are benign, a small percentage carry a risk of malignancy. The Thyroid Imaging Reporting and Data System (TIRADS) is a classification system used to assess the risk of thyroid nodules based on their ultrasound characteristics. TIRADS 5 is the highest category, indicating that a nodule is highly suspicious for malignancy. In this article, we’ll explore the key aspects of TIRADS 5 thyroid nodules, including their causes, symptoms, treatment options, and the role of biopsy in their evaluation.

TIRADS 5 Thyroid Nodule Overview

TIRADS 5 nodules represent the most suspicious category in the TIRADS classification system, with a risk of malignancy ranging from 60% to over 80%. These nodules exhibit multiple high-risk features on ultrasound, making them a priority for further investigation and management. While the majority of TIRADS 5 nodules are cancerous, early detection and appropriate treatment can significantly improve outcomes.

Causes of TIRADS 5 Thyroid Nodules

TIRADS 5 nodules are typically caused by underlying factors that lead to abnormal cell growth in the thyroid gland. The key causes include:

• Genetic Mutations: Mutations in certain genes, such as BRAF, RAS, or RET/PTC, can lead to the formation of malignant thyroid nodules. These mutations disrupt normal cell regulation, leading to uncontrolled growth and the development of cancerous nodules.
• Radiation Exposure: Exposure to radiation, particularly during childhood, is a well-known risk factor for developing malignant thyroid nodules. Individuals who have been exposed to radiation therapy or nuclear accidents may be at higher risk.
• Chronic Inflammation: Chronic inflammation of the thyroid gland, such as in Hashimoto’s thyroiditis, can increase the risk of developing malignancies within the gland. This inflammation may contribute to cellular changes that lead to the formation of TIRADS 5 nodules.
• Iodine Deficiency: Iodine is essential for thyroid function, and its deficiency can lead to goiter and the development of nodules. While most iodine-deficient nodules are benign, some can progress to malignancy, particularly if they exhibit suspicious characteristics.

Symptoms of TIRADS 5 Thyroid Nodules

TIRADS 5 nodules can sometimes present with symptoms, although many are discovered incidentally during imaging for other reasons. When symptoms do occur, they may include:

• Visible Lump in the Neck: A noticeable lump or swelling in the neck is a common sign of a thyroid nodule. TIRADS 5 nodules, due to their potential malignancy, may be firmer or irregular in shape.
• Difficulty Swallowing or Breathing: If the nodule is large or located near the esophagus or trachea, it can cause difficulty swallowing (dysphagia) or breathing, particularly when lying down.
• Hoarseness: A nodule pressing on the recurrent laryngeal nerve can lead to hoarseness or changes in voice. This is a concerning symptom that warrants immediate evaluation.
• Throat Pain or Discomfort: Some patients with TIRADS 5 nodules may experience a sense of pressure, discomfort, or pain in the throat, especially if the nodule is large or growing rapidly.

Treatment of TIRADS 5 Thyroid Nodules

The management of TIRADS 5 nodules is critical due to their high risk of malignancy. Treatment options typically include:

• Surgical Removal: Surgery is often the first line of treatment for TIRADS 5 nodules. Depending on the size, location, and biopsy results, a surgeon may perform a lobectomy (removal of one lobe of the thyroid) or a total thyroidectomy (removal of the entire thyroid gland). In cases where malignancy is confirmed, surgery helps to remove the cancerous tissue and prevent its spread.
• Radioactive Iodine Therapy: After surgery, radioactive iodine therapy may be used to destroy any remaining thyroid tissue or cancer cells. This treatment is particularly useful in cases of papillary or follicular thyroid cancer, which are more likely to absorb iodine.
• Thyroid Hormone Suppression Therapy: Patients may be prescribed thyroid hormone suppression therapy to reduce TSH levels, which can stimulate the growth of any remaining cancerous cells. This therapy helps lower the risk of recurrence.
• Ongoing Monitoring: Regular follow-up with ultrasound and blood tests is essential to monitor for recurrence or the development of new nodules. Even after successful treatment, ongoing vigilance is necessary to ensure the best possible outcome.

For details, check here and here.

TIRADS 5 Thyroid Nodule Biopsy

Given the high suspicion of malignancy associated with TIRADS 5 nodules, a fine-needle aspiration (FNA) biopsy is almost always recommended. The biopsy involves using a thin needle to extract cells from the nodule for examination under a microscope. The goals of the biopsy are to:

• Confirm Malignancy: The primary purpose of an FNA biopsy is to determine whether the nodule is malignant. The presence of cancerous cells in the biopsy sample confirms the diagnosis and guides treatment.
• Assess Nodule Characteristics: The biopsy can provide additional information about the nodule’s characteristics, such as its cellular composition and aggressiveness. This information is crucial for planning the most effective treatment strategy.
• Guide Surgical Decision-Making: Biopsy results help determine the extent of surgery needed, such as whether to remove just one lobe or the entire thyroid gland. They also guide the need for additional treatments like radioactive iodine therapy.

Conclusion

TIRADS 5 thyroid nodules represent the most suspicious category within the TIRADS classification system, with a significant risk of malignancy. Understanding the causes, recognizing symptoms, and pursuing appropriate treatment and biopsy are critical steps in managing these nodules effectively. Early detection and intervention can significantly improve outcomes, making it essential for patients with TIRADS 5 nodules to work closely with their healthcare providers to develop a comprehensive treatment plan. Regular monitoring and follow-up care are also key to ensuring long-term health and well-being.

Reference

1. Kallepalli VSD, Nelson T, Sanniyasi S. Analysis of Thyroid Imaging Reporting and Data System Criteria and Its Correlation With the Pathological Results. Cureus. 2023 Jun 8;15(6):e40117. doi: 10.7759/cureus.40117. PMID: 37425497; PMCID: PMC10329402.
2. Abolhasani Foroughi A, Mokhtari M, Heidari E, Nazeri M, Rastgouyan H, Babaei A. Concordance between TIRADS and Cytology in Thyroid Nodule. Iran J Otorhinolaryngol. 2022 Nov;34(125):295-302. doi: 10.22038/IJORL.2022.57663.2984. PMID: 36474488; PMCID: PMC9709392.
3. A Rozenbaum, C Buffet, C Bigorgne, B Royer, A Rouxel, M Bienvenu, N Chereau, F Menegaux, L Leenhardt, G Russ, Outcomes of active surveillance of EU-TIRADS 5 thyroid nodules, European Journal of Endocrinology, Volume 184, Issue 5, May 2021, Pages 677–686, retrieved from here